Buscar Close Search
Buscar Close Search
Profile Picture for Wang

Dan Wang PhD

Research Focus - Gene Therapy

  • Gene therapy using adeno-associated virus (AAV) vectors
  • Neurological and metabolic diseases
  • Therapeutic genome editing
  • RNA-based approaches to treating genetic diseases

Representative Publications

  • Wang J, Zhang Y, Mendonca CA, Yukselen O, Muneeruddin K, Ren L, Liang J, Zhou C, Xie J, Li J, Jiang Z, Kucukural A, Shaffer SA, Gao G, Wang D. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. 2022. Read Publication

In the News

  • Guangping Gao and Dan Wang partner with ASC Therapeutics to develop novel gene therapy for maple syrup urine disease

    Guangping Gao and Dan Wang partner with ASC Therapeutics to develop novel gene therapy for maple syrup urine disease

    UMass Medical School researchers Guangping Gao, PhD, and Dan Wang, PhD, are working with ASC Therapeutics to bring a gene therapy for maple syrup urine disease (MSUD) to the clinic.

    Read more
  • UMass Chan establishes gene therapy collaborative research agreement with Pfizer

    UMMS establishes gene therapy collaborative research agreement with Pfizer

    UMass Medical School has entered into a three-year, collaborative research agreement with Pfizer to evaluate determinants that influence the manufacturing quality and yield of viral vectors used in gene therapy. The research at UMMS is being performed under the direction of Guangping Gao, PhD, and Dan Wang, PhD.

    Read more
  • Flotte lab to develop gene therapy models for genetic lung disease

    Flotte lab to develop gene therapy models for genetic lung disease

    Researchers from UMass Chan Medical School have received a five-year $13.6 million program project grant from the National Heart, Lung and Blood Institute to develop new gene therapy models for alpha-1 antitrypsin deficiency, a chronic, debilitating genetic lung disease that shortens the lifespan.

    Read more
  • UMass Chan research supports development of new suppressor-tRNA-based gene therapies

    UMass Chan research supports development of new suppressor-tRNA-based gene therapies

    Guangping Gao, PhD, and Dan Wang, PhD, show the first evidence that a suppressor transfer RNA therapy, delivered by a recombinant adeno-associated virus, can restore protein production up to six months after treatment in a mouse model of the rare genetic disease mucopolysaccharidosis type I.

    Read more
  • UMass Chan BRIDGE Fund commits $2M in six faculty projects

    UMass Chan BRIDGE Fund commits $2M in six faculty projects

    BRIDGE Innovation and Business Development at UMass Chan Medical School has set aside nearly $2 million in funding for six faculty-led research projects that hold promise for translation to clinical application and commercialization.  

    Read more